ErbB2/Her2 Antibody (191924) [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB2 is widely expressed in epithelial cells and has also been found to be over-expressed in a large number of breast carcinomas. Among ErbB family members, ErbB2 is unique in that it has no identified ligands. Rather, ErbB2 heterodimerizes with the other members of the ErbB family (ErbB1 (EGF R), ErbB3, ErbB4) to form higher affinity signaling complexes. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. Interestingly, this same three amino acid signal has also been found in ErbB1 and ErbB4. Phosphoinositide 3-kinase has been shown to play a role in ErbB2 signal transduction. The cytoplasmic domain of ErbB2 has been shown to associate with beta-catenin and plakoglobin. Human ErbB2 consists of 1255 amino acids (aa) with a 21 aa signal sequence, a 631 aa extracellular domain, a 23 aa transmembrane region, and a 580 aa cytoplasmic domain. ErbB2 can be shed from the cell surface by proteolytic cleavage by an unidentified protease. ErbB2 appears to play roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation (1-10).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 5 applications: Flow Cytometry, ICC, Immunoprecipitation, Luminex Development, Western Blot.

Showing Publications 1 - 10 of 15. Show All 15 Publications. Collapse Publications.

Publications using MAB1129	Applications	Species
Devra Olson, Janelle Taylor, Kelsi Willis, Kelly Hensley, Sean Allred, Margo Zaval et al. HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer Cancer Res Commun 2023-09-25 [PMID: 37721518]
Nana Lyu, Bernadette Pedersen, Elena Shklovskaya, Helen Rizos, Mark P. Molloy, Yuling Wang SERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment Exploration (Beijing) 2022-06-01 [PMID: 37323700]
Z Yang, L Li, A Turkoz, P Chen, R Harari-Ste, M Bobbin, O Stefanson, H Choi, V Pietrobon, B Alphson, A Goswami, V Balan, A Kearney, D Patel, J Yang, D Inel, V Vinod, A Cesano, B Wang, KH Roh, LS Qi, FM Marincola Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers Journal of Translational Medicine, 2021-11-07;19(1):459. 2021-11-07 [PMID: 34743703] (Flow Cytometry, Human)	Flow Cytometry	Human
Daniel Y. Joh, Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell et al. Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates npj Breast Cancer 2021-07-02 [PMID: 34215753]
M Kuroda, P Halfmann, Y Kawaoka HER2-mediated enhancement of Ebola virus entry PLoS Pathog, 2020-10-14;16(10):e1008900. 2020-10-14 [PMID: 33052961] (Flow Cytometry, ICC, Human, Mouse)	Flow Cytometry, ICC	Human, Mouse
A Kulukian, P Lee, J Taylor, R Rosler, P de Vries, D Watson, A Forero-Tor, S Peterson Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models Mol. Cancer Ther., 2020-04-01;19(4):976-987. 2020-04-01 [PMID: 32241871] (Flow Cytometry, Human)	Flow Cytometry	Human
SS Islam, M Uddin, ASM Noman, H Akter, NJ Dity, M Basiruzzma, F Uddin, J Ahsan, S Annoor, AA Alaiya, M Al-Alwan, H Yeger, WA Farhat Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1 EBioMedicine, 2019-05-10;0(0):. 2019-05-10 [PMID: 31085100] (ICC, Western Blot, Human)	ICC, Western Blot	Human
Allison M. Claas, Lyla Atta, Simon Gordonov, Aaron S. Meyer, Douglas A. Lauffenburger Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition Cellular and Molecular Bioengineering 2018-12-01 [PMID: 30524510]
TS Klann, JB Black, M Chellappan, A Safi, L Song, IB Hilton, GE Crawford, TE Reddy, CA Gersbach CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome Nat. Biotechnol., 2017-04-03;0(0):. 2017-04-03 [PMID: 28369033] (Flow Cytometry, Human)	Flow Cytometry	Human
E Fina, A Necchi, S Bottelli, C Reduzzi, S Pizzamigli, C Iacona, MG Daidone, P Verderio, V Cappellett Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods Dis. Markers, 2017-02-22;2017(0):3414910. 2017-02-22 [PMID: 28321147] (Flow Cytometry, Human)	Flow Cytometry	Human
HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone Cancer Res., 2016-10-28;0(0):. 2016-10-28 [PMID: 27793843] (Flow Cytometry, Human)	Flow Cytometry	Human
Thilo Riedl, Egon van Boxtel, Martijn Bosch, Paul W. H. I. Parren, Arnout F. Gerritsen High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe J Biomol Screen 2016-01-01 [PMID: 26518032]
Jin-Hee Han, L. Sudheendra, Hee-Joo Kim, Shirley J. Gee, Bruce D. Hammock, Ian M. Kennedy Ultrasensitive On-Chip Immunoassays with a Nanoparticle-Assembled Photonic Crystal ACS Nano 2012-10-23 [PMID: 22957818]
Nora Theilacker, Eric E. Roller, Kristopher D. Barbee, Matthias Franzreb, Xiaohua Huang Multiplexed protein analysis using encoded antibody-conjugated microbeads Journal of The Royal Society Interface 2011-08-07 [PMID: 21247950]
Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay Drug Dev Technol, 2010-02-01;8(1):27-36. 2010-02-01 [PMID: 20035613] (Immunoprecipitation, Luminex Development, Human)	Immunoprecipitation, Luminex Development	Human
Show All 15 Publications. Collapse Publications.

Array MAB1129

• ErbB2/Her2 Antibodies
• ErbB2/Her2 Antibody Pair
• ErbB2/Her2 Lysate
• ErbB2/Her2 Proteins
• ErbB2/Her2 ELISAs
• ErbB2/Her2 Proteins and Enzymes